Is Recursion Pharmaceuticals Inc (RXRX) overvalued? · rev $58.8M
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
This page asks whether Recursion Pharmaceuticals Inc (RXRX) looks expensive on cached numbers — not a short thesis.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
RXRX currently screens at market cap $1.75B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RXRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RXRX stock page for the full model, not this heading.
Not investment advice.